Master License Agreement



 Exhibit 10.20 
 MASTER LICENSE AGREEMENT 
 THIS AGREEMENT by and between SurModics, Inc., a corporation of the State of Minnesota,
which has an office at 9924 West 74th Street, Eden Prairie, MN 55344, (hereinafter referred to as SURMODICS), and Innercool Therapies, Inc., a corporation of the State of California, which has an office at 3931 Sorrento Valley Blvd., San
Diego, CA 92121 (hereinafter referred to as INNERCOOL). 
 WHEREAS, SURMODICS is engaged in biological, chemical and technical research and has
developed a body of technology and know-how, including reagents, processes and devices which the parties believe will improve the performance of various products and processes of INNERCOOL. 
 WHEREAS, the technology of SURMODICS includes confidential information (including trade secrets and other know-how) which is proprietary to SURMODICS and SURMODICS is in
the process of securing patent coverage for certain items of its technology, and continues to maintain the confidentiality of other portions of its technology. 
 WHEREAS, INNERCOOL (formerly known as Del Mar Medical Technologies) and SURMODICS are parties to a Mutual Confidential Disclosure Agreement dated December 18, 1998 (“Prior Disclosure Agreement”); 
 WHEREAS, INNERCOOL may desire to acquire additional licenses under SURMODICS’ know-how and patent rights, such licenses to be added to this Master Agreement;

 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below and for other good and valuable consideration of which receipt is
acknowledged, the parties agree as follows: 
 1. DEFINITIONS 
 The following definitions apply to this Agreement and to all addenda thereto: 
 a. “Affiliate”
means any entity which owns at least 50% of, is at least 50% owned by, or is under common (at least 50%) ownership with INNERCOOL. 
 b.
“Effective Date” means the date upon which this Agreement is fully executed. 
 c. “Know-how” means SURMODICS’ trade
secrets and other technical information relating to the surface-treatment of medical devices and which SURMODICS has the right to transmit to others. Know-how includes but is not limited to information contained in pending patent applications of
Patent Rights and information that is Confidential Information as defined in Paragraph 13. 
  

 1 








 d. “Licensed Products” means each of the separately sold Medical Products specifically
described in Attachment Bl, B2, and so forth, and which: 
 i. but for the license granted herein the manufacture, use or sale would infringe
(or a surface treatment process employed to produce a product or a reagent used in such process would infringe) any claim of Patent Rights, or 
 ii. are produced through the use of SURMODICS’ Know-how. 
 e. “Licensed Product Effective Date” for each license
granted herein shall mean the date specified in the respective Attachment Bl, B2, and so forth. 
 f. “Manufacturer” means a
non-Affiliate third party which manufactures Licensed Products for INNERCOOL pursuant to a separate agreement with INNERCOOL, and subject to the execution by the Manufacturer and SURMODICS of the document entitled “Manufacturer Agreement and
SurModics’ Consent” attached hereto as Attachment C. 
 g. “Medical Products” means products that are specifically
described and defined in Attachment B1, B2, and so forth. 
 h. “Net Sales” means the total actual billing for sales of Licensed
Products, less the following deductions where they are applicable with respect to such billings and when separately shown on invoices: 
 i.
discounts actually allowed and taken; 
 ii. any customs, duties, taxes or other governmental excise or charge upon or measured by the
production, sale, transportation, delivery or use of Licensed Product and actually paid by INNERCOOL; 
 iii. amounts allowed or credited on
rejections or returns; 
 iv. transportation charges prepaid or allowed. 
 Notwithstanding the above, if any Licensed Product is sold both separately and as an integral part of a combination product containing one or more
integral components in addition to that Licensed Product, then Net Sales of that Licensed Product resulting from sales of that combination product will be calculated by multiplying the Net Sales for the combination product as calculated above by the
fraction A/B where A is the invoice price of the Licensed Product as sold separately and B is the invoice price of the combination product. 
 A Licensed Product shall be considered sold when it is shipped or when it is invoiced, whichever is earlier. To assure SURMODICS the full royalty payment contemplated in this Agreement, INNERCOOL agrees that in the event any Licensed
Product is sold to an 
  

 2 








 Affiliate for purposes of resale, Earned Royalties for that Licensed Product shall be computed upon the
selling price at which such Licensed Product would ordinarily be sold to a non-Affiliate, rather than on the selling price of INNERCOOL to the Affiliate. 
 i. “Patent Rights” means the patent application(s) and patent(s) identified in Attachment A hereof, together with all foreign counterparts, divisions, and continuation applications based thereon, any patent
issuing on any of said applications, and any reissues or extensions based on any of such patents. 
 j. “Valid Claim” means a claim
of Patent Rights that has not been held invalid or unenforceable by a court of competent jurisdiction beyond possibility of appeal, or which has not expired due to non-payment of maintenance fees beyond possibility of reinstatement based on
unintentional delay. 
 2. LICENSE 
 a. With respect to the Licensed Product defined in each of Attachments B1, B2, and so forth, SURMODICS grants to INNERCOOL, a separate worldwide license under SURMODICS’ Patent Rights and Know-how to make, have
made for it by a Manufacturer as defined herein, use and sell that Licensed Product. The license granted herein is expressly limited to the specific Licensed Products defined herein, and does not include the right to sublicense. Additional terms of
each license are set out in the respective Attachments Bl, B2, and so forth. To the extent of any inconsistency between the terms set forth in the text of this Agreement and the terms set forth in Attachments Bl, B2, and so forth, the terms set
forth in the text of this Agreement shall be controlling. Each such license shall be effective as of its Licensed Product Effective Date. 
 b. Subject to the limited license granted herein, SURMODICS shall retain all rights to the Patent Rights and Know-how. SURMODICS shall retain the right to use Patent Rights and Know-how for its own research purposes. 
 c. INNERCOOL shall notify SURMODICS, in advance and in writing, of any change in the location of the production of a Licensed Product or any new location
to be used for the production of a Licensed Product. 
 3. LICENSE FEES 
 For each license granted by SURMODICS, INNERCOOL shall pay to SURMODICS a License Fee as set out in the respective Attachment Bl, B2, and so forth.

  

 3 








 4. ROYALTIES 
 For each license granted herein, INNERCOOL shall pay to SURMODICS a royalty for each quarter calendar year during the term of this License Agreement which will be the greater of the royalties of Paragraphs 4(a) or
4(b). 
 a. Earned Royalties shall be calculated as provided for in the respective Attachment Bl, B2, and so forth. No more than one Earned
Royalty shall be paid by INNERCOOL for any Licensed Product. However, if any Licensed Product is covered by more than one Attachment B1, B2, and so forth, then the Earned Royalty rate shall be the highest rate specified for such Licensed Product.

 b. Minimum Royalties shall be paid for each Licensed Product as provided for in the respective Attachment Bl, B2, and so forth. 

5. ROYALTY PAYMENTS, REPORTS, RECORDS 
 a. During the term of this Agreement, and for each license granted hereunder, INNERCOOL will make written reports and payments to SURMODICS within thirty (30) days after the last day of each calendar quarter ending March 31,
June 30, September 30, and December 31. Each such report shall state the Net Sales, unit volumes, Earned Royalty, corrections of error in prior royalty payments, and data and calculations used by INNERCOOL to determine such payments
for each of the licenses corresponding to the respective Attachments B1, B2, and so forth. Each report shall be accompanied by payment in full of the royalty due SURMODICS for that quarter. The December 31 quarterly report shall also include a
summary progress report regarding INNERCOOL’s relevant developmental, manufacturing scale-up, regulatory affairs, and marketing activities with respect to all Licensed Products along with a summary forecast of projected sales of Licensed
Products and a nonbinding forecast of reagent usage for the next calendar year. 
 b. INNERCOOL will maintain, for a period of five
(5) years following each sale of Licensed Product, true and accurate records supporting the reports and payments made under this Agreement. SURMODICS shall have the right to carry out an audit of such records no more frequently than once per
calendar year by a certified public accountant of its choice. Such accountant shall have reasonable access to INNERCOOL’s offices and the relevant records, files and books of account, and such accountant shall have the right to examine any
other records reasonably necessary to determine the accuracy of the calculations provided by INNERCOOL under Paragraph 5(a). Such audit shall be at SURMODICS’ expense except that if an underpayment error is found for any twelve month period
that exceeds 5% of the payment made to SURMODICS for that period, then INNERCOOL will bear the cost of such audit. 
 c. All royalties on
sales of each Licensed Product to be paid to SURMODICS by INNERCOOL under this Agreement shall be paid in U.S. Dollars to SURMODICS in the 
  

 4 








 United States. For the purpose of calculating Earned Royalties on sales outside the United States for any
calendar quarter, INNERCOOL shall utilize the average rate of exchange on the last business day of that calendar quarter as quoted in the Wall Street Journal. 
 d. Any sum required under U.S. tax laws (or the tax laws of any other government) to be withheld by INNERCOOL from payment for the account of SURMODICS shall be promptly paid by INNERCOOL for and on behalf of
SURMODICS to the appropriate tax authorities, and INNERCOOL shall furnish SURMODICS with official tax receipts or other appropriate evidence issued by the appropriate tax authorities sufficient to enable SURMODICS to support a claim for income tax
credit in respect to any sum so withheld. 
 6. DEVELOPMENT FEES 
 INNERCOOL agrees to pay SURMODICS for development efforts (“Development Fees”) while working on INNERCOOL’s products at SURMODICS’ then standard hourly rate for development efforts provided,
however, that such development effort is pursuant to a mutually agreed upon project plan. SURMODICS’ standard hourly rate includes direct labor costs plus direct labor overhead. SURMODICS shall additionally charge direct materials plus direct
materials overhead of fifteen percent (15%). Direct materials may include expenses such as travel and special equipment, but only as mutually agreed upon in writing. SURMODICS shall invoice INNERCOOL monthly for such Development Fees and payment
shall be made within thirty (30) days thereafter. 
 Notwithstanding the above, SURMODICS will not charge INNERCOOL for the initial
disclosure of such Know-how. Such initial disclosure of Know-how shall include the preparation and delivery to INNERCOOL of a ‘Technology Transfer Document” which shall contain information relating to the procedures and techniques used by
SURMODICS to coat such Licensed Product. SURMODICS will provide up to two days of training in the use of SURMODICS’ coating procedures covered in the Technology Transfer Document. Such training shall be at SURMODICS’ facility and be
offered to a reasonable number (three or less) of INNERCOOL employees who will be using or implementing such coating procedures. Travel and accommodations for such INNERCOOL employees will be at INNERCOOL’s expense. At INNERCOOL’s request,
SURMODICS will send a coating engineer to the INNERCOOL manufacturing facility or to one designated Manufacturer facility in the United States for up to two days to review the production line, advise on reagent handling and to provide other advice
that may assist INNERCOOL in the implementation of the coating process into INNERCOOL’s manufacturing process. Travel and accommodations for such SURMODICS employee will be at SURMODICS’ expense. 
 7. TERM 
 a. Unless earlier terminated, each
license herein granted shall begin upon the Licensed Product Effective Date set out in the respective Attachment Bl, B2, and so forth, and shall 
  

 5 








 extend for each Licensed Product so licensed until expiration of the last to expire patent of Patent
Rights that covers that product or for a period of fifteen (15) years following the first bona fide commercial sale of such Licensed Product, whichever is longer. 
 b. Upon expiration of the full term of the license granted herein for any Licensed Product, and upon full payment by INNERCOOL to SURMODICS of any monies due under this Agreement, the license with respect to Know-how
licensed herein for that Licensed Product shall be deemed paid up and non-exclusive (if any such license was exclusive), and SURMODICS may negotiate additional license agreements with any other party for SURMODICS’ surface modifications.

 8. PATENTS 
 a. INNERCOOL shall
see to it that all Licensed Products sold by INNERCOOL shall be appropriately marked with the applicable patent numbers, in conformity with applicable law. 
 b. SURMODICS recognizes that it is an objective of INNERCOOL to obtain patents on technology that it develops concerning chemicals having latent reactive groups and their uses. INNERCOOL recognizes that a vital part
of SURMODICS’ business involves the licensing of others under SURMODICS’ patents and know-how to make, use and sell products, and that it is an objective of SURMODICS to enable its present and future licensees to exploit patent licenses
from SURMODICS to produce and sell products without interference from any patent that INNERCOOL might obtain. A purpose of this Paragraph 8(b) is to establish a system under which each party may accomplish its respective objective. 
 i. “INNERCOOL Latent Reactive Chemical Patents” (INNERCOOL LRC Patents) means patents which (a) claim inventions conceived or first reduced
to practice during the term of this Agreement solely by one or more INNERCOOL employees or others who are required to assign inventions to INNERCOOL, and (b) claim inventions relating to chemical species having photo-reactive or other latent
reactive groups for the purpose of bonding chemicals such as synthetic polymers and biologically active materials onto surfaces or into matrices or to other molecules, the use of such chemical species, or the products resulting from such use, and
(c) which could be infringed by the manufacture, use or sale of any product or process covered by any claim of any patent that SURMODICS has the right to license to others or may have licensed to others. 
 ii. During the term of this Agreement, INNERCOOL will provide SURMODICS with a copy of each proposed patent application for a INNERCOOL LRC Patent, and
SURMODICS will provide comments concerning such application, including comments regarding inclusion of SURMODICS’ Confidential Information, prior work done by SURMODICS in connection with the claimed invention, and the state 
  

 6 








 of the art. No application for an INNERCOOL LRC Patent shall be made without SURMODICS’ prior
written permission. If SURMODICS can fairly show that it had substantial knowledge of the invention of any INNERCOOL LRC Patent application before receiving from INNERCOOL that patent application, SURMODICS shall promptly notify INNERCOOL and the
parties shall cooperate in comparing records of conception of that invention to determine in good faith which party was the earliest to conceive the invention. 
 iii. SURMODICS shall have and is hereby granted a noncancelable, nonexclusive, worldwide license, with the right to sublicense, to make, have made for it, use and sell products and processes covered by each INNERCOOL
LRC Patent to the extent that such manufacture, use or sale also is covered by any claim of any patent that SURMODICS has the right to license to others or may have licensed to others. If INNERCOOL was the earliest to conceive the invention of that
patent, then the license granted to SURMODICS, and SURMODICS’ right to sublicense, shall exclude the right to manufacture, use or sell Medical Products. 
 iv. In return for such license, SURMODICS will pay INNERCOOL a total of five percent (5%) of the royalties (regardless of the number of INNERCOOL LRC Patents that are licensed to SURMODICS or the number of
licenses involved) that SURMODICS receives from its sublicensees based on sales by its sublicensees of products that but for such sublicenses would infringe any Valid Claim of INNERCOOL LRC Patents. Notwithstanding the above, if SURMODICS was the
earliest to conceive the invention of any INNERCOOL LRC Patent, then the license granted to SURMODICS shall be considered paid-up. 
 c. The
parties agree to execute and exchange upon request such documents as may be necessary or desirable to carry out the provisions of Paragraph 8(b). 
 d. Notwithstanding the provisions of Paragraph 12(c), in the event that any third party infringes or threatens to infringe the Patent Rights, a party shall notify the other party in writing of such infringement which becomes known to it and
the parties shall discuss together by whom and what action shall be taken, if any. This paragraph shall not obligate either party to undertake, join in, or fund any litigation. Either party shall undertake to provide the other party with any
documents or other reasonable, non-financial assistance, as may be required should the other party choose to undertake, join in, or fund any litigation. 
 9. ALLOCATION OF ROYALTIES 
 It is agreed that royalties payable under the applicable Attachment B shall be allocated
seventy percent (70%) to Know-how licensed herein and thirty percent (30%) to Patent Rights licensed herein. The Earned Royalty rate with respect to any Licensed Product shall be prospectively reduced to seventy percent (70%) of the
Earned Royalty rate set out in Paragraph 4(a) and the respective Attachments Bl, B2, and so forth, to the extent that and 
  

 7 








 during the term that neither the manufacture, nor the use, nor the sale of that specific Licensed Product
(or a surface treatment process or a reagent used in such process) is covered by any Valid Claim of Patent Rights. The provisions of this Paragraph 9 shall not apply to payment of Minimum Royalties as provided in Paragraph 4(b) and the respective
Attachments Bl, B2, and so forth. 
 10. TERMINATION 
 a. For each license granted herein: 
 i. INNERCOOL shall have the right to terminate the respective
Attachment B1, B2, and so forth, under which such license was granted, but only in its entirety, at any time upon ninety (90) days advance written notice. Upon termination of such license, INNERCOOL shall have no further rights under Patent
Rights or Know-how. However, INNERCOOL shall be allowed to sell any inventory of Licensed Products existing at the time of termination for a period of twelve (12) months thereafter (thereafter destroying any remaining inventory), provided
INNERCOOL accounts for such sales of inventory and pays SURMODICS the appropriate Earned Royalty for such sales as set out in Paragraph 4(a) of this Agreement. 
 ii. SURMODICS may terminate this Agreement in whole or with respect to any license granted herein upon thirty (30) days written notice for any material breach or default by INNERCOOL, including without
limitation, failure to comply with the confidentiality provisions of Paragraph 13, failure to make reports and payments when due, failure to pay Minimum Royalties, and withholding or notice of intent to withhold any royalties provided for in this
Agreement. Said termination under this Paragraph 10(a)(ii) shall become effective at the end of the thirty (30) day period unless during that period INNERCOOL shall first cure such breach or default. 
 iii. Upon termination of any license under any of the provisions of this Paragraph 10, but subject to the provisions of Paragraph l0(a)(i), referring to
the sale of inventory, INNERCOOL shall cease making, having made for it, using and selling the Licensed Products of such license that are produced through the use of SURMODICS’ Know-how. SURMODICS shall have the right to seek equitable relief
to enforce the provisions of this Paragraph 10(a)(iii). 
 b. Either party may terminate this Agreement if the other party hereto is involved
in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of its business. 
 c. Notwithstanding the
provisions of Paragraph 20, failure of INNERCOOL to initiate bona fide commercial sales of any Licensed Product by the date set out for that Licensed Product in the respective Attachment B1, B2, and so forth, to this Agreement shall permit SURMODICS
to terminate the license for that Licensed Product upon thirty (30) days written notice at any time prior to the date INNERCOOL begins bona fide commercial sales of that Licensed Product. 
  

 8 








 d. In the event that all licenses granted herein are terminated, SURMODICS shall have the right to
terminate this Agreement in its entirety upon written notice. 
 11. CONTINUING OBLIGATIONS SUBSEQUENT TO TERMINATION 
 a. Upon any termination of this Agreement or any of the licenses granted herein, the following rights and obligations shall continue to the degree
necessary to permit their complete fulfillment or discharge: 
 i. SURMODICS’ right to receive and INNERCOOL’s obligation to pay
royalties to the extent owed; and 
 ii. INNERCOOL’s obligation to maintain records and SURMODICS’ right to audit under Paragraph 5,
with respect to sales made and to be made under Paragraph 10(a)(i); and 
 iii. Any cause of action or claim of either party, accrued or to
accrue, because of any breach or default by the other party; and 
 iv. The parties’ obligation to maintain confidentiality under
Paragraph 13; and 
 v. INNERCOOL’s obligation to forebear from use of SURMODICS’ Know-how as provided in Paragraph 10(a)(iii); and

 vi. The parties’ obligations under Paragraph 8(b), with respect to filing patent applications and under Paragraph 8(b) and Attachment
Bl - Paragraph 7 with respect to the payment of royalties on issued patents. 
 b. Within thirty (30) days of the date of termination of
this Agreement, each party shall return to the other party all copies of documents and other materials containing or disclosing any of the other party’s Confidential Information; provided, however, that each party shall be entitled to retain
one copy of such Confidential Information for archival purposes only. 
 12. REPRESENTATIONS AND WARRANTIES 
 a. Each party warrants to the other that it has not accepted and will not accept commitments or restrictions with respect to its rights or obligations
under this Agreement which will materially affect the value of the rights granted by SURMODICS nor the obligations undertaken by INNERCOOL. 
  

 9 








 b. Each party has the full and unrestricted right to enter into this Agreement. 
 c. Nothing in this Agreement shall be construed as: 
 i. A warranty or representation by SURMODICS as to the validity or scope of any Patent Rights; or 
 ii. A warranty or representation
that anything made, used, sold, or otherwise disposed of, or any process practiced, under any License granted in this Agreement is or will be free from infringement of patents of third persons; or 
 iii. A requirement that SURMODICS file any patent application, secure any patent, or maintain any patent in force; or 
 iv. An obligation to bring or prosecute actions or suits against third parties for infringement of any patent; or 
 v. An obligation to furnish any manufacturing or technical information not encompassed within Know-how; or 
 vi. Conferring any right on either party to use in advertising, publicity, or otherwise any trademark or trade name of the other; or 
 vii. Granting by implication, estoppel, or otherwise any licenses or rights under patents or other proprietary information of SURMODICS other than those
included within Patent Rights and Know-how. 
 d. WITH RESPECT TO PHOTO-REACTIVE REAGENTS SUPPLIED AT ANY TIME BY SURMODICS, SURMODICS
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE. NOTWITHSTANDING ANYTHING TO THE CONTRARY, SURMODICS SHALL NOT BE LIABLE FOR INCIDENTAL,
CONSEQUENTIAL, SPECIAL, EXTRAORDINARY OR PUNITIVE DAMAGES OF ANY DESCRIPTION, WHETHER FOR DAMAGE TO REPUTATION OR GOODWILL, LOST PROFITS, CLAIMS OF THIRD PARTIES OR OTHERWISE, WHETHER SUCH ASSERTED DAMAGE PURPORTS TO BE BASED ON WARRANTY OR
GUARANTEE, INDEMNITY OR OTHER CONTRACT, CONTRIBUTION, NEGLIGENCE OR OTHER TORT, OR OTHERWISE. 
 e. SURMODICS does not make any
representations, extend any warranties of any kind, either express or implied, or assume any responsibilities whatever with respect to use, sale, or other disposition by INNERCOOL or its vendees or transferees of Licensed Products incorporating or
made by use of the Patent Rights and Know-how licensed under this Agreement. 
  

 10 








 f. INNERCOOL represents that it will take action to reasonably bring to market and to sell Licensed
Product throughout INNERCOOL’s world-wide marketing territory during the term of this Agreement. Failure to adequately promote and market Licensed Product may, at SURMODICS’ option, be interpreted as a material breach or default of this
Agreement. SURMODICS expects INNERCOOL to demonstrate appropriate product development activities, participate in clinical trials, submit appropriate regulatory or governmental filings for appropriate marketing clearances, integrate the Licensed
Product into INNERCOOL’s manufacturing operations, educate appropriate sales and marketing staff, and introduce and actively market the Licensed Product upon completion of product development and obtaining appropriate regulatory approvals.

 13. CONFIDENTIALITY 
 a. Each
party agrees to retain in confidence all Know-how and other information received from the other, including without limitation, information required to be maintained in confidence under prototype development or manufacturing scale-up or post scale-up
relationships between the parties, for a period of fifteen (15) years from the date of disclosure or five (5) years from the date of termination of this Agreement, whichever is longer. Each party agrees not to disclose any of such Know-how
or other information to third parties nor to use the same except in accordance with this Agreement. Each party’s obligation of non-disclosure and non-use shall not apply to information which: 
 i. at the time of its disclosure to the receiving party is available to the public; 
 ii. after disclosure becomes available to the public through no fault of the receiving party; 
 iii. the receiving party can show was in its possession at the time of disclosure to it by the other; 
 iv. the receiving party can show was received by it from a third party without breach of a confidential obligation; or 
 v. the receiving party is compelled by application of law or legal process to divulge, but the receiving party shall provide the disclosing party with
advance written notice before divulging the information to enable the disclosing party to seek a protective order or employ other means to preserve the confidential nature of that information. 
  

 11 








 Even after any of such information becomes available to the public, each party shall not disclose without
the other’s prior written approval the fact that such information was furnished by or originated with the other. 
 b. For the purpose of
this entire Paragraph 13, Know-how or other information which is specific shall not be deemed to be within any of the specified exceptions merely because it is embraced by more general information in such exception. In addition, any combination of
features shall not be deemed to be within any of the specified exceptions merely because individual features are in such exception, but only if the combination itself and its principle of operation are in such exception. 
 c. Notwithstanding the above, INNERCOOL specifically agrees that it will not disclose to any Affiliates or other third party any of SURMODICS’
Know-how relating to the manufacture of SURMODICS’ chemical reagents, the precise chemical composition of such reagents, how such reagents are tested, how they are quality controlled, and any other specific information concerning the production
of such reagents. 
 d. The provisions of this entire Paragraph 13 shall survive termination of this Agreement for any reason. 
 e. Nothing herein shall in any way affect the obligations of the parties under any prior secrecy or confidential disclosure agreements, including the
Prior Disclosure Agreement, which obligations shall continue in accordance with the terms of each such agreement to the extent not inconsistent with the present Agreement. 
 14. ASSIGNMENT 
 This Agreement shall be binding upon and inure to the benefit of the parties
hereto and their successors and permitted assigns. Either party may assign its rights and obligations under this Agreement to a financially responsible third party, but only in connection with a complete transfer to the third party of the business
to which this Agreement pertains. The assigning party will so inform the other party to this Agreement without delay of any assignment made in accordance with the conditions of this Agreement. This Agreement shall not otherwise be assignable by
either party without the prior written consent of the other party. Any and all assignments of this Agreement or any interest therein not made in accordance with this paragraph shall be void. 
 15. GOVERNMENT APPROVAL 
 INNERCOOL shall have
the sole responsibility, at INNERCOOL’s sole expense, for obtaining any government approvals that may be required for the investigation or marketing of Licensed Products. 
  

 12 








 16. PRODUCT LIABILITY 
 INNERCOOL will defend and indemnify SURMODICS against all losses, liabilities, lawsuits, claims, expenses (including attorney’s fees), costs, and judgments incurred through personal injury, property damage, or
other claims of third parties, arising from the design, manufacture, use, or sale of Licensed Products, except which are proximately caused solely by SURMODICS’ negligent conduct. 
 17. NO WAIVER 
 Any waiver of any term or condition of this Agreement by either party shall not
operate as a waiver of any other or continued breach of such term or condition, or any other term or condition, nor shall any failure to enforce a provision hereof operate as a waiver of such provision or of any other provision hereof. 

18. NOTICES 
 All communications or other
notices required or permitted under this Agreement shall be in writing and shall be deemed to be given when personally delivered, or when mailed by registered or certified mail, postage prepaid, and addressed as follows: 
 If to SURMODICS: 
 License
Administration 
 SurModics, Inc. 
 9924 West 74th Street 
 Eden Prairie, MN 55344 
 If to INNERCOOL: 
 License
Administration 
 Innercool Therapies, Inc. 
 3931 Sorrento Valley Blvd. 
 San Diego, CA 92121 
 Either party shall have the right to change the person and/or address to which notices hereunder shall be given, by notice to the other party in the
manner set out above. 
 19. CAPTIONS 
 The captions and headings of this Agreement are for convenience only and shall in no way limit or otherwise affect any of the terms or provisions contained herein. 
  

 13 








 20. FORCE MAJEURE 
 Neither party shall be liable for failure to perform as required by any provisions of this Agreement where such failure results from a cause beyond such party’s reasonable control such as acts of God, regulation
or other acts of civil or military authority, required approval(s) of government bodies, fires, strikes, floods, epidemics, quarantine restrictions, riot, delays in transportation and inabilities to obtain necessary labor, materials, or
manufacturing facilities. In the event of any delay attributable to any of the foregoing causes, the time for performance affected thereby shall be extended for a period equal to the time lost by reason of such delay. The cumulative effect of all
such delays under this Paragraph 20 shall not exceed one (1) year. 
 21. NO AGENCY 
 Nothing in this Agreement authorizes either SURMODICS or INNERCOOL to act as agent for the other as to any matter, or to make any representations to any
third party indicating or implying the existence of any such agency relationship. SURMODICS and INNERCOOL shall each refrain from any such representations. The relationship between SURMODICS and INNERCOOL is that of independent contractors.

 22. SEVERABILITY 
 Should any
provision of this Agreement, or the application thereof, to any extent be held invalid or unenforceable, the remainder of this Agreement and the application thereof other than such invalid or unenforceable provisions shall not be affected thereby
and shall continue valid and enforceable to the fullest extent permitted by law or equity. 
 23. GOVERNING LAW 
 This Agreement shall for all purposes be governed and interpreted in accordance with the laws of the State of Minnesota, except for its conflict of laws
provisions. 
 24. ARBITRATION 
 a.
In the event of any dispute concerning this Agreement, including its interpretation, performance, breach or termination, the procedures of this Paragraph 24 shall apply; provided, however, that either party shall have the unrestricted right at any
time to seek a court injunction prohibiting the other party from making unauthorized disclosure or use of Confidential Information as provided for in Paragraph 13 or unauthorized use of SURMODICS’ Know-how as provided for in Paragraph
10(a)(iii). 
  

 14 








 b. Both parties will use good faith and reasonable efforts to resolve any dispute informally and as soon
as practical. If any such dispute is not resolved informally within a reasonable period, then an officer from each party, having authority to resolve the dispute, will meet at a mutually agreeable time and place to attempt to resolve the dispute.

 c. If the parties are unable to resolve a dispute as provided immediately above, either party may submit the dispute for resolution by
mandatory, binding arbitration in the city of Minneapolis, MN (or such other place as the parties may mutually agree) under the auspices of the American Arbitration Association under its Commercial Arbitration Rules. Each party shall select one
independent, qualified arbitrator and the two arbitrators so selected shall then select a third arbitrator in accordance with the Commercial Rules. Each party reserves the right to object to any individual arbitrator (no matter by whom chosen) who
has been employed by or affiliated with a competing organization. 
 d. The arbitrators, who shall act by majority vote, shall be empowered
to decree any and all relief of an equitable nature, including but not limited to temporary restraining orders, temporary injunctions, and/or permanent injunctions, and shall also be able to award damages, with or without an accounting of costs.
Judgment on the award rendered by the arbitrator(s) may be entered into any court having jurisdiction thereof. Each party shall bear its own costs and divide other reasonable arbitrator costs equally. 
 25. ENTIRE AGREEMENT 
 This Agreement, together
with the Prior Disclosure Agreement and all addenda, attachments, and writings required or contemplated hereby, constitutes the entire agreement between the parties with respect to the Licenses granted herein, and no party shall be liable or bound
to the other in any manner by any warranties, representations or guarantees except as specifically set forth herein. This Agreement shall not be altered or otherwise amended except by an instrument in writing signed by both parties. 
 IN WITNESS WHEREOF, the parties have executed this Agreement on the date last written below. 
  

					
	SurModics, Inc.	 		 	Innercool Therapies, Inc.
			
	 /s/ Walter H. Diers Jr
	 		 	 /s/ John Dobak

	Signature	 		 	Signature
			
	 Walter H. Diers Jr
	 		 	 John Dobak

	Printed Name	 		 	Printed Name
			
	 Vice President
	 		 	 CEO

	Title	 		 	Title
			
	 1 December 1999
	 		 	 11/29/99

	Date	 		 	Date

  

 15 








 ATTACHMENT A 
 SurModics, Inc. U.S. Patents (may be listed under previous name, BSI Corporation) 
  

	1.	METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES 


	 	U.S.	Patent No. 4,973,493 issued 11/27/90 

  

	2.	BIOCOMPATIBLE COATINGS FOR SOLID SURFACES 


	 	U.S.	Patent No. 4,979,959 issued 12/25/90 

  

	3.	PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS 


	 	U.S.	Patent No. 5,002,582 issued 3/26/91 

  

	4.	BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES 


	 	U.S.	Patent No. 5,217,492 issued 6/8/93 

  

	5.	METHOD OF BIOMOLECULE ATTACHMENT TO HYDROPHOBIC SURFACES 


	 	U.S.	Patent No. 5,258,041 issued 11/2/93 

  

	6.	BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT 


	 	U.S.	Patent No. 5,263,992 issued 11/23/93 

  

	7.	RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION 


	 	U.S.	Patent No. 5,414,075 issued 5/9/95 

  

	8.	SUBSTRATE SURFACE PREPARATION 


	 	U.S.	Patent No. 5,512,329 issued 4/30/96 

  

	9.	PREPARATION OF CROSSLINKED MATRICES CONTAINING COVALENTLY IMMOBILIZED CHEMICAL SPECIES AND UNBOUND RELEASABLE CHEMICAL SPECIES 


	 	U.S.	Patent No. 5,563,056 issued 10/08/96 

  

	10.	RESTRAINED MULTIFUNCTIONAL REAGENT FOR SURFACE MODIFICATION 


	 	U.S.	Patent No. 5,637,460 issued 6/10/97 

  

	11.	PHOTOACTIVATABLE WATER SOLUBLE CROSSLINKING AGENTS CONTAINING AN ONIUM GROUP 


	 	U.S.	Patent No. 5,714,360 issued 02/03/98 

  

 16 








 SurModics, Inc. U.S. Patent Applications (may be listed under previous name, BSI Corporation) 
  

	1.	VIRUS INACTIVATING COATINGS 

 Filed 6/7/95 
  

	2.	METHOD AND IMPLANTABLE ARTICLE FOR PROMOTING ENDOTHELIALIZATION 

 Filed 5/26/95 
 SurModics, Inc. Foreign Patents (may be listed under previous name, BSI Corporation) 
  

	1.	IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES 

 Canadian Patent No. 1305068, issued 7/14/92 
 Australian Patent No. 615637, issued 10/16/87 
 EPO Patent No. 0326579, issued 1/11/95 
  

	2.	BIOMOLECULE ATTACHED TO A SOLID SURFACE BY MEANS OF A SPACER AND METHODS OF ATTACHING BIOMOLECULES TO SURFACES 

 Canadian Patent No. 1335721, issued 5/30/95 
 SurModics, Inc. Foreign Patent Applications (may be listed under previous name, BSI Corporation) 
  

	1.	BIOCOMPATIBLE COATINGS 

 Filed in Canada, Europe, Japan,
Denmark, and Norway 
  

	2.	PREPARATION OF POLYMERIC SURFACES 

 Filed in Canada,
Europe, Japan, Denmark, and Norway 
  

	3.	IMMOBILIZATION OF CHEMICAL SPECIES IN CROSSLINKED MATRICES 

 Filed in Canada, Europe, Australia, Japan 
  

	4.	IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES 

 Filed in Japan 
  

	5.	RESTRAINED MULTIFUNCTIONAL REAGENTS FOR SURFACE MODIFICATION 

 Filed in Canada, Europe, Australia and Japan 
  

 17 








 ATTACHMENT B1 
 Heating/Cooling Catheter 
  

	1.	MEDICAL PRODUCTS 

 “Medical Products”
means a single-use, temporary (less than 7 days) catheter placed within the vascular system that is designed, labeled and approved (as may be required by appropriate governmental authority prior to sale) for the purpose of in situ heating or cooling
of blood. For the avoidance of doubt, such catheters shall not be designed, labeled or approved for the purpose of infusing or delivering any therapeutic or embolic agents or for the delivery or placement of permanently implantable therapeutic
devices (including embolic devices), while the distal tip of such catheter resides at or above the common carotid artery. For purposes of this Attachment B1, saline solutions and contrast media (for placement or diagnostic purposes) are not
considered therapeutic agents. 
  

	2.	LICENSED PRODUCT 

 “Licensed Products”
means Medical Products which are surface-treated with photo-reactive polyvinylpyrrolidone, photo-reactive heparin, diphoto diquat (photo-reactive crosslinking compound) or any combination of these photo-reactive reagents. 
  

	3.	GRANT OF LICENSE 

 The license granted under this
Attachment is non-exclusive. 
  

	4.	LICENSE FEES 

 INNERCOOL will pay to SURMODICS a
total of $50,000 in nonrefundable License Fees for this Attachment due according to the following schedule: 
 $25,000 upon execution of this
Attachment. 
 $25,000 upon first commercial sale of Licensed Product or two years from the date of execution of this Attachment, whichever is
earlier. 
  

	5.	ROYALTY PAYMENTS 

 INNERCOOL shall pay to SURMODICS
a royalty, for the Patent Rights and Know-how license granted herein, which will be the greater of Paragraphs 5(a) or 5(b) as follows: 
 a.
Earned Royalties calculated as a percentage of Net Sales ($U.S.) of Licensed Products sold in each calendar year. The percentage to be used in each calculation during each calendar year shall be based upon the cumulative Net Sales of Licensed
Product in the calendar year as follows: 
  

 18 









				
	 Net Sales in Each Calendar Year
	  	Earned Royalty Rate	 
	On the first $15,000,000	  	2.50	%
	On the next $15,000,000	  	2.25	%
	On Net Sales over $30,000,000	  	2.00	%

 b. Quarterly Minimum Royalties for all Attachment B1 Licensed Products during the periods specified as follows:

  

				
	 Minimum Royalty Periods
	  	Quarterly Minimum Royalty
	January 1, 2002 to December 31, 2002	  	$	5,000
	January 1, 2003 to December 31, 2003	  	$	10,000
	January 1, 2004 to December 31, 2004	  	$	20,000

 For the quarter calendar year commencing with January 1, 2005, and each year thereafter, the
quarter calendar year Minimum Royalty shall be the prior year’s quarterly Minimum Royalty adjusted by a percentage equal to the percentage change in the “Consumer Price Index For All Urban Consumers” for the prior calendar year as
reported by the U.S. Department of Labor. 
  

	6.	PERFORMANCE 

 a. Failure of INNERCOOL to begin bona
fide commercial sales by January 1, 2003, of a Licensed Product as defined in this Attachment, shall permit SURMODICS to terminate the license for that Licensed Product upon thirty (30) days written notice at any time prior to the date
INNERCOOL begins bona-fide commercial sales of that Licensed Product. 
 b. If, after January 1, 2003, there are four
(4) consecutive quarters in which INNERCOOL fails to generate Earned Royalties under Paragraph 5(a) of this Attachment then upon thirty (30) days written notice given to INNERCOOL, the license granted herein shall, at SURMODICS’
option, be terminated. 
  

	7.	ADDITIONAL LICENSE 

 With respect to patentable
inventions related to Medical Products, exclusive of surface modifications, conceived or first reduced to practice during the term of this Attachment Bl solely by SURMODICS employees, SURMODICS hereby agrees to provide INNERCOOL with a
non-exclusive, worldwide license to make, have made for it by a Manufacturer as defined herein, use and sell products and processes covered by such patent. Such license provides no rights to sublicense. In return for such license, any such patent
shall be considered a part of Patent Rights. Such license, and INNERCOOL’s obligation to pay royalties thereunder, shall survive termination of this Agreement, except termination for breach by INNERCOOL of royalty obligations hereunder.

  

 19 









	8.	OTHER 

 SURMODICS represents that it currently owns
no other or further patents or patent applications not included in Patent Rights that would be infringed by the manufacture, use, offer for sale or sale of the Licensed Products of this Attachment B1. 
 The Licensed Product Effective Date of this Attachment shall be the date last written below or the date on which SURMODICS receives all payments due upon execution of
this Attachment, whichever is later. 

					
			
	 SurModics, Inc.
	 		 	 Innercool Therapies, Inc.

			
	 /s/ Walter H. Diers Jr
  
	 		 	 /s/ John Dobak
  

	 Signature
	 		 	 Signature

			
	 Walter H. Diers Jr
  
	 		 	 John Dobak
  

	 Printed Name
	 		 	 Printed Name

			
	 Vice President
  
	 		 	 CEO
  

	 Title
	 		 	 Title

			
	 1 December 1999
  
	 		 	 11/29/99
  

	 Date
	 		 	 Date


  

 20 








 ATTACHMENT C 
 Manufacturer Agreement and SurModics’ Consent 
                                       
                                        
                                        
                                   (“Manufacturer”) which is
located at 
 ________________________________________________________________________________________________________________________________________________

 states, that it has read and understands the Master License Agreement between SurModics, Inc. (“SURMODICS”) and Innercool Therapies, Inc.
(“INNERCOOL”), and that it desires to manufacture Licensed Product as permitted in that Master License Agreement. In return for SURMODICS’ consent to manufacture Licensed Product solely for sale by INNERCOOL, and for other valuable
consideration of which receipt and sufficiency are acknowledged, Manufacturer agrees with SURMODICS that Manufacturer shall faithfully carry out and be bound by the obligations imposed on INNERCOOL, including, without limitation, Paragraphs 8, 10,
11, 13, 14, 16 and 24 of the Master License Agreement, to the extent applicable to Manufacturer’s activities. 
 Manufacturer further agrees: 
  

	 	1.	SURMODICS confidential information and SURMODICS Know-how will be provided only to employees with the above identified facility who have a need to know such information for the
specific purpose of manufacturing Licensed Products. 

  

	 	2.	Photo-reactive chemical compounds manufactured by SURMODICS shall not be transferred by Manufacturer to any other facility of Manufacturer without the express written permission of
SURMODICS. 

  

	 	3.	Employees of Manufacturer will make no attempt to reverse engineer, in whole or in part, any confidential information (including photo-reactive compounds) of SURMODICS.


 This Agreement shall be effective upon the last date written below, and shall terminate automatically and without notice upon the
termination or expiration of the relevant license under the Master License Agreement. 
  

					
	 Consented to by
 SurModics, Inc.
	 		 	 Agreed to by
 Manufacturer

	  
	 		 	  

	Signature	 		 	Signature
			
	  
	 		 	  

	Printed Name	 		 	Printed Name
			
	  
	 		 	  

	Title	 		 	Title
			
	  
	 		 	  

	Date	 		 	Date

  

 21